UNSPSC 51101645: Chiniofon

This classification denotes an antiprotozoal agent with the molecular formula C9H6INO4S.CHO3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98F8Y85B6W, chemically known as 5-quinolinesulfonic acid, 8-hydroxy-7-iodo- but generally known as chiniofon, which bears US NIH Compound Identifier 11042. European Medicines Agency schedules Chiniofon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12428MIG.

UNSPSC 51101645 Chiniofon, a Commodity code, encompasses pharmaceutical products and related medical supplies that state and local governments procure for healthcare delivery, emergency response, and community health initiatives. Recent solicitations show state and local agencies buying generic pharmaceuticals, over-the-counter products, naloxone, emergency medical supplies, and specialty pharmaceuticals through both direct procurement and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances. The Texas Health and Human Services Commission and Minnesota Department of Administration serve as anchor buyers, signaling state-level pharmaceutical strategy and bulk purchasing; county and municipal agencies, such as Seminole County, Florida and the City of Tampa, procure supplies for specific operational units—emergency response divisions, community health centers, and healthcare facilities.

Recent activity spans Florida, Texas, and Minnesota. Representative opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the County Community Health Building and a response deadline of July 26, 2023; the City of Tampa's ITB 26P00145 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000 and a sheltered small local business enterprise set-aside with a 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and award effective July 1, 2026. The Texas HHS Commission issued an exploratory RFI (HHS0017013) in April 2026 regarding direct-to-manufacturer prescription programs, indicating emerging state interest in alternative pharmaceutical supply models outside traditional pharmacy benefit managers and group purchasing organizations.